Target intelligence / Profile preview

Heavy metal ion chelation (null)

Target
null
Molecular classification
Other (mechanistic process/chemical strategy), Not a molecular receptor, enzyme, transporter, channel, or transcription factor
01

Overview

Heavy metal ion chelation is a chemical process whereby a chelating agent binds to heavy metal ions via multiple coordination bonds, forming stable, often ring-shaped complexes[5][1][2]. This process underlies chelation therapy, a medical intervention to treat acute or chronic heavy metal poisoning by enhancing excretion of toxic metals such as lead, mercury, cadmium, or arsenic[1][2]. Chelating agents may have additional biological effects, including reducing oxidative stress and inflammation stemming from redox-active metals in tissues[1]. The action of chelators depends on their molecular structure, selectivity for metal ions, solubility, and pharmacokinetic properties[2]. Clinical chelation strategies must balance efficacy in metal removal with risks related to redistribution, essential element depletion, and direct toxicity from the chelators themselves[1][2][5][4].

Other names
Chelationmetal ion chelationchelation therapyheavy metal sequestration
02

Mechanism of action

Formation of stable metal-chelator complexes, reducing free ion toxicity and enabling renal/biliary excretion. Redistribution of metal ions across compartments (e.g., removing ions from protein aggregates). Inhibition/passivation of metalloenzymes via chelating inhibitor fragments.

03

Biological functions

Detoxification of heavy metalsModulation of oxidative stressReduction of inflammation caused by metal toxicityMobilization and excretion of metal ions
04

Disease associations

Heavy metal poisoningNeurodegenerative disease (mechanistic implications in redistribution or toxicity of metal ions in brain)Cardiovascular disease (possible in some chelation therapy trials)Other (prevention/treatment of chronic metal toxicities)
05

Safety considerations

Chelator toxicity (e.g., nephrotoxicity, allergic reactions, hypocalcemia for EDTA)Redistribution of metals causing secondary toxicity (e.g., metals mobilized before excretion)Non-selective chelation/binding of essential trace elements (calcium, magnesium, zinc) leading to deficiencyMetabolic disturbances due to altered metal homeostasis
06

Interacting drugs

Ethylenediaminetetraacetic acid (EDTA)

7 more in the full profile.

07

Biomarkers

Urinary or blood levels of heavy metals (e.g., lead, mercury, cadmium)Decreased tissue metal burden (measured after chelation)

Beyond the preview

Go deeper on Heavy metal ion chelation (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heavy metal ion chelation (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call